SCHEMBL1865540

SCHEMBL1865540

CNC(=O)c1ccc(C(F)(F)F)c(-c2ccc3c(Nc4ncc(C(F)(F)F)cn4)ccnc3c2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 10/20 0.51
SCN9A Q15858 2/20 0.41
BRAF P15056 2/20 0.39
KDR P35968 4/20 0.37
PRKD3 O94806 2/20 0.37
MAP4K4 O95819 2/20 0.37
GSK3A P49840 2/20 0.37
GSK3B P49841 2/20 0.37
AURKB Q96GD4 2/20 0.37
PRKD2 Q9BZL6 2/20 0.37
CLK4 Q9HAZ1 2/20 0.37
PLK4 O00444 1/20 0.37
DYRK3 O43781 1/20 0.37
CHEK2 O96017 1/20 0.37
FGFR1 P11362 1/20 0.37
CDK2 P24941 1/20 0.37
FLT4 P35916 1/20 0.37
CLK2 P49760 1/20 0.37
LIMK1 P53667 1/20 0.37
CSNK1G2 P78368 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1858989 0.90 TRPV1 (0.53) TRPV1KDRPRKD3MAP4K4GSK3A
SCHEMBL1860850 0.90 TRPV1 (0.66) TRPV1SCN9AGSK3AGSK3BCLK4
SCHEMBL12665999 0.89 TRPV1 (0.43) TRPV1SCN9ABRAFKDRPRKD3
SCHEMBL1865741 0.88 TRPV1 (0.49) TRPV1BRAFGAK
SCHEMBL1859733 0.85 TRPV1 (0.52) TRPV1SCN9AKDRPRKD3MAP4K4
SCHEMBL1864049 0.84 TRPV1 (0.46) TRPV1SCN9AKDRPRKD3MAP4K4
SCHEMBL1861672 0.84 TRPV1 (0.56) TRPV1GAK
SCHEMBL1858558 0.83 TRPV1 (0.66) TRPV1SCN9ACDK2
SCHEMBL1858310 0.80 TRPV1 (0.54) TRPV1GSK3AGSK3BCLK4DYRK3
SCHEMBL1861178 0.79 TRPV1 (0.69) TRPV1GSK3AGSK3BCLK4DYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935702-B2 Substituted biaryl quinolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2011-05-03 US disclosed
US-7935702-B2 Substituted biaryl quinolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2011-05-03 US disclosed
EP-1811845-A4 SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORP (US) 2009-07-15 EP disclosed
EP-1811845-A2 SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2007-08-01 EP disclosed
US-20060111337-A1 Substituted biaryl quinolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2006-05-25 US disclosed
WO-2006042289-A2 SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111337-A1 Substituted biaryl quinolin-4-ylamine analogues PIGS, GPR52, GPR174 TRPV1 549/4885SCN9A 1615/4885BRAF 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.